Citation: | MA Yunyun, JIANG Zijuan, LI Ping, WANG Xiaoxiao, ZHANG Luoluo. Research hotspot of moyamoya disease: a visualized analysis based on CiteSpace software[J]. Chinese Journal of General Practice, 2024, 22(11): 1971-1975. doi: 10.16766/j.cnki.issn.1674-4152.003777 |
[1] |
烟雾病治疗中国专家共识编写组. 烟雾病治疗中国专家共识[J]. 国际脑血管病杂志, 2019, 27(9): 645-650.
Writing group for Chinese expert consensus statement on the diagnosis and treatment of moyamoya disease. Chinese expert consensus statement on the diagnosis and treatment of moyamoya disease[J]. International Journal of Cerebrovascular Diseases, 2019, 27(9): 645-650.
|
[2] |
FUJIMURA M, TOMINAGA T, KURODA S, et al. 2021 Japanese Guidelines for the management of moyamoya disease: guidelines from the research committee on moyamoya disease and Japan Stroke Society[J]. Neurol Med Chir (Tokyo), 2022, 62(4): 165-170. doi: 10.2176/jns-nmc.2021-0382
|
[3] |
GONZALEZ N R, AMIN-HANJANI S, BANG O Y, et al. Adult moyamoya disease and syndrome: current perspectives and future directions: a scientific statement from the American Heart Association/American Stroke Association[J]. Stroke, 2023, 54(10): e465-e479.
|
[4] |
SUN Y X, ZHOU G Y, FENG J N, et al. Incidence and prevalence of moyamoya disease in urban China: a nationwide retrospective cohort study[J]. Stroke Vasc Neurol, 2021, 6(4): 615-623. doi: 10.1136/svn-2021-000909
|
[5] |
GRAF J, SCHWITALLA J C, ALBRECHT P, et al. Misdiagnoses and delay of diagnoses in Moyamoya angiopathy: a large Caucasian case series[J]. J Neurol, 2019, 266(5): 1153-1159. doi: 10.1007/s00415-019-09245-9
|
[6] |
雷霆, 张华楸, 黄逸民, 等. 烟雾病发病机制研究和诊疗进展[J]. 中华实验外科杂志, 2023, 40(9): 1698-1700.
LEI T, ZHANG H Q, HUANG Y M, et al. Comentary on mechanical investigation and progress of therapeutic methods of Moyamoya disease[J]. Chinese Journal of Experimental Surgery, 2023, 40(9): 1698-1700.
|
[7] |
IHARA M, YAMAMOTO Y, HATTORI Y, et al. Moyamoya disease: diagnosis and interventions[J]. Lancet Neurol, 2022, 21(8): 747-758. doi: 10.1016/S1474-4422(22)00165-X
|
[8] |
ISHISAKA E, WATANABE A, MURAI Y, et al. Role of RNF213 polymorphism in defining quasi-Moyamoya disease and definitive moyamoya disease[J]. Neurosurg Focus, 2021, 51(3): E2. DOI: 10.3171/2021.5.FOCUS21182.
|
[9] |
HIRUMA M, WATANABE N, MITSUMATSU T, et al. Clinical features of Moyamoya disease with Graves' disease: a retrospective study of 394, 422 patients with thyroid disease[J]. Endocr J, 2023, 70(2): 141-148. doi: 10.1507/endocrj.EJ22-0319
|
[10] |
JEONG W, SEONG G M, OH J H, et al. A case report of critical ischemic stroke in Moyamoya-like vasculopathy accompanied by systemic lupus erythematosus[J]. Encephalitis, 2022, 2(1): 24-27. doi: 10.47936/encephalitis.2021.00150
|
[11] |
BOLEM N, NGA V D W, CHOU N, et al. Coexisting Moyamoya syndrome and type 1 diabetes mellitus: a case report and review of the literature[J]. Asian J Neurosurg, 2020, 15(1): 194-197. doi: 10.4103/ajns.AJNS_218_19
|
[12] |
SHANG S L, ZHOU D, YA J Y, et al. Progress in moyamoya disease[J]. Neurosurg Rev, 2020, 43(2): 371-382. doi: 10.1007/s10143-018-0994-5
|
[13] |
KLEINDORFER D O, TOWFIGHI A, CHATURVEDI S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association[J]. Stroke, 2021, 52(7): e364-e467.
|
[14] |
NGUYEN V N, MOTIWALA M, ELARJANI T, et al. Direct, indirect, and combined extracranial-to-intracranial bypass for adult Moyamoya disease: an updated systematic review and meta-analysis[J]. Stroke, 2022, 53(12): 3572-3582. doi: 10.1161/STROKEAHA.122.039584
|
[15] |
YU J, ZHANG J B, LI J L, et al. Cerebral hyperperfusion syndrome after revascularization surgery in patients with Moyamoya disease: systematic review and meta-analysis[J]. World Neurosurg, 2020, 135: 357-366. e4. DOI: 10.1016/j.wneu.2019.11.065.
|
[16] |
陈传玉, 邓克学, 邱峻, 等. 动脉自旋标记技术对缺血型和出血型烟雾病患者脑灌注情况的评估[J]. 中华全科医学, 2019, 17(12): 2001-2003, 2012. doi: 10.16766/j.cnki.issn.1674-4152.001112
CHEN C Y, DENG K X, QIU J, et al. Evaluation of cerebral perfusion in patients with ischemic and hemorrhagic moyamoya disease by arterial spin labeling[J]. Chinese Journal of General Practice, 2019, 17(12): 2001-2003, 2012. doi: 10.16766/j.cnki.issn.1674-4152.001112
|
[17] |
LIU E H, LIU C Y, JIN L D, et al. Clinical value of the systemic immune-inflammation index in Moyamoya disease[J]. Front Neurol, 2023, 14: 1123951. DOI: 10.3389/fneur.2023.1123951.
|
[18] |
WANG Q N, ZOU Z X, WANG X P, et al. Endothelial Progenitor cells induce angiogenesis: a potential mechanism underlying neovascularization in encephaloduroarteriosynangiosis[J]. Transl Stroke Res, 2021, 12(2): 357-365. doi: 10.1007/s12975-020-00834-9
|
[19] |
FEUGRAY G, MIRANDA S, DUCHEZ V L, et al. Endothelial progenitor cells in autoimmune disorders[J]. Stem Cell Rev Rep, 2023, 19(8): 2597-2611. doi: 10.1007/s12015-023-10617-y
|
[20] |
TINELLI F, NAVA S, ARIOLI F, et al. Vascular remodeling in moyamoya angiopathy: from peripheral blood mononuclear cells to endothelial cells[J]. Int J Mol Sci, 2020, 21(16): 5763. DOI: 10.3390/ijms21165763.
|
[21] |
GORLA G, GARROZZINI T, POLLACI G, et al. Increase of circulating endothelial progenitor cells and released angiogenic factors in children with Moyamoya arteriopathy[J]. Int J Mol Sci, 2023, 24(2): 1233. DOI: 10.3390/ijms24021233.
|
[22] |
NAKAMURA H, SATO K, YOSHIMURA S, et al. Moyamoya disease associated with Graves' disease and down syndrome: a case report and literature review[J]. J Stroke Cerebrovasc Dis, 2021, 30(1): 105414. DOI: 10.1016/j.jstrokecerebrovasdis.2020.105414.
|
[23] |
SLINGERLAND A L, KARSTEN M B, SMITH E R, et al. Two sides of a coin: case report of unilateral synangiosis and contralateral stroke highlighting consequences of disease progression and efficacy of revascularization in sickle cell disease-associated Moyamoya syndrome[J]. Acta Haematol, 2022, 145(4): 458-464. doi: 10.1159/000521361
|